help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on July 19, 2007
Endocrinology, doi:10.1210/en.2007-0175
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/10/4687    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bozaoglu, K.
Right arrow Articles by Segal, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bozaoglu, K.
Right arrow Articles by Segal, D.

Submitted on February 7, 2007
Accepted on July 9, 2007

Chemerin is a novel adipokine associated with obesity and metabolic syndrome

Kiymet Bozaoglu, Kristy Bolton, Janine McMillan, Paul Zimmet, Jeremy Jowett, Greg Collier, Ken Walder, and David Segal*

Metabolic Research Unit, School of Exercise and Nutrition Sciences, Deakin University, Waurn Ponds, Victoria, Australia, International Diabetes Institute, Caulfield, Victoria, Australia, ChemGenex Pharmaceuticals, Geelong, Victoria, Australia

* To whom correspondence should be addressed. E-mail: dsegal{at}deakin.edu.au.

Soluble protein hormones are key regulators of a number of metabolic processes including food intake and insulin sensitivity. We have used a signal sequence trap (SST) to identify genes that encode secreted or membrane bound proteins in Psammomys obesus, an animal model of obesity and type 2 diabetes (T2D). Using this SST, we identified the chemokine chemerin as being a novel adipokine. Gene expression of chemerin and its receptor, CMKLR1, were significantly higher in adipose tissue of obese and type 2 diabetic P. obesus compared to lean, normoglycemic P. obesus. Fractionation of P. obesus adipose tissue confirmed that chemerin was predominantly expressed in adipocytes while CMKLR1 was expressed in both adipocytes and stromal-vascular cells of adipose tissue. In 3T3-L1 adipocytes, chemerin was markedly induced during differentiation while CMKLR1 was down-regulated during differentiation. Serum chemerin levels were measured by ELISA in human plasma samples from 114 subjects with T2D and 142 normal glucose tolerant controls. Plasma chemerin levels were not significantly different between subjects with type 2 diabetes and normal controls. However, in normal glucose tolerant subjects, plasma chemerin levels were significantly associated with body mass index, circulating triglycerides and blood pressure. Here we report, for the first time, that chemerin is an adipokine and circulating levels of chemerin is associated with several key aspects of metabolic syndrome.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
Y. Wu and C. M. Smas
Wdnm1-like, a new adipokine with a role in MMP-2 activation
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E205 - E215.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society